Scilex is distributing roughly 10.7 million Semnur shares to its stockholders — but it holds approximately 186 million. That gap is not a rounding error; it is the entire strategic logic of the transaction. Scilex retains an overwhelming majority stake in Semnur while handing shareholders just enough equity to create a public float and generate OTC trading activity around a subsidiary that has completed a Phase 3 trial but has yet to file for FDA approval of SEMDEXA, its epidural dexamethasone gel for sciatica.
The structure is a partial spin-in-place. By paying a one-for-one stock dividend against Scilex common shares with a June 1 record date, the board creates a technically separate public entity without surrendering control or forcing a dilutive capital raise at Semnur. SEMDEXA received Fast Track designation in 2017 and finished its Phase 3 study, yet no NDA has materialized. Packaging Semnur as a standalone OTC-traded company generates independent valuation pressure — and, more practically, gives the subsidiary a currency for future financing without touching Scilex’s own balance sheet. That is the move here: unlock Semnur’s pipeline value on a separate ledger while Scilex’s commercial portfolio of ZTlido, ELYXYB, and Gloperba continues carrying operating revenue.
The solvency carve-out in the board resolution deserves attention. Payment is explicitly conditioned on no material change to the solvency or surplus analysis presented to directors, and the record date remains revocable for any reason before the payment date. That language is unusually prominent for a dividend announcement and signals that Scilex’s financial cushion is thin enough that counsel insisted on a hard exit clause. For a company running three commercial products in the competitive non-opioid pain space, that caveat matters more than the distribution ratio itself.
The single consequence to watch is whether Semnur files an NDA for SEMDEXA within twelve months of achieving independent trading status. If the spin is purely a financing mechanism with no regulatory submission on the horizon, the OTC float will collapse, dragging Scilex’s implied stub value with it. An NDA filing is the only event that justifies the structural complexity here.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
